Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
2 Magnificent Growth Stocks With Room to Run
08:45am, Wednesday, 27'th Mar 2024
Small-cap growth stocks could be on the brink of a major trend reversal. Prime Medicine and Tilray Brands, two small-cap stocks that appear significantly undervalued, could be smart buys ahead of a po
Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging
02:44pm, Thursday, 14'th Mar 2024
A short squeeze is a financial phenomenon where rapidly increasing prices force short sellers to buy back stocks, pushing prices even higher. This situation often arises from a large number of investo
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
02:00pm, Friday, 01'st Mar 2024
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifeti
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
08:00am, Friday, 01'st Mar 2024
-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus
Prime Medicine to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 28'th Feb 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine Announces Pricing of Upsized Public Offering
11:50pm, Wednesday, 14'th Feb 2024
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 14'th Feb 2024
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
08:11am, Sunday, 28'th Jan 2024
Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF
08:00am, Thursday, 25'th Jan 2024
BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis.
2 gene editing stocks to keep on your 2024 watchlist
08:23am, Tuesday, 23'rd Jan 2024
Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CR
Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know
07:33pm, Tuesday, 09'th Jan 2024
The mean of analysts' price targets for Prime Medicine, Inc. (PRME) points to an 111.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 02'nd Jan 2024
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
AI In Biotech: A Revolutionary Leap Forward Or Just Another Buzzword?
02:45pm, Friday, 01'st Dec 2023
AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovati
